Specialty Pharmacy

Pharmacists should be asking their patients with HIV not only if they are taking their medications, but also how they are taking them.

The FDA is requiring Concordia Pharmaceuticals to conduct studies on its hyperkalemia treatment, sodium polystyrene sulfonate (Kayexalate), to see if it binds to other medications administered by mouth, which would decrease potency.

Lawmakers are seeking input on potential improvements for the medication therapy management (MTM) program for Medicare Part D beneficiaries.

Program takes advantage of neuroplasticity to train the brain to work more efficiently.

The future of highly effective cholesterol-lowering drug.

Top news of the week in cancer drug development.

Perceived discrimination is one of the main barriers to obtaining health care services for underrepresented populations.

Senator Tim Kaine (D-VA) discussed Medicaid expansion, the Affordable Care Act, and politics at America's Health Insurance Plans' National Conference on Medicaid.

Individuals with autism spectrum disorders should be further monitored by proper diagnostic methods.

Carfilzomib, pomalidomide, and dexamethasone regimen safe and well tolerated during recent study.

Top stories of the week on Specialty Pharmacy Times.

Finding treatments that deliver better glycemic control is critical.

Some health care systems use outdated approaches to racial categorization that obscure care disparities.

Rare ALK mutation allows patients to live an average of 4 years with the disease controlled.

More than half of patients did not return to physicians for follow-up care.

Women increasingly choosing surgery to remove both breasts.

Caregivers are urged to utilize adequate mental health screening approaches.

Downing Labs, a retail pharmacy based in Texas, has issued a voluntary recall of all lots of sterile products.

Hepatic decompensation and liver failure in patients with underlying liver cirrhosis more common with drug regimen.

Researchers hope new treatment delivery system will reduce administration down to once or twice per year.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses how technology can be utilized to improve patient outcomes.

Veltassa binds with potassium in the gastrointestinal tract to reduce absorption.

Research may improve the design of pharmaceuticals for leukemia and other types of cancer.

Many RA treatments suppress the immune system, leaving patients at risk for contracting a potentially fatal infection.

Breast Cancer and the Environment Research Program will focus on racially and ethnically diverse communities and expand the study of risk factors.

Panel discusses treatment barriers during annual NASP conference.

Factor X deficiency prevents blood from clotting properly.

Atheer Kaddis, PharmD, senior vice president of Business Development and Sales at Diplomat, discusses services offered by Diplomat's Hospital Specialty Program.

Despite new advanced immunotherapies, surgical resection still is the most effective treatment for abdominal metastatic melanoma.

Pfizer asked to provide additional safety analyses for proposed indication.